Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

Vu L. Truong, Ph.D.

Founder, Chief Executive Officer, and Director

Dr. Truong is a founder of Aridis and recently elected to the CEO position in 2014 after having served as the company's Chief Scientific Officer for the past 9 years. He has over 15 years experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to Medimmune), and Medimmune (sold to Astra Zeneca). He has a life-long interest and research experience in infectious diseases, focusing on the development of innovative human monoclonal antibodies and vaccines designed to address life threatening infections. His product development experience includes FluMist™, Synagis™ mAb, and a number of other monoclonal antibody based therapeutics. Dr. Truong is the principal architect of the Aridis technologies, which includes a range of anti-infective products and pharmaceutical processing technologies. He received his Ph.D. in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.


Paul-Andre de Lame, M.D.

Chief Medical Officer

Dr. de Lame is an intensive care medical expert with strong experience in cardiovascular medicine and infectious diseases.  He was a former executive at Merck and Warner Lambert (Pfizer) where he  focused on clinical development at Merck and Warner-Lambert (Pfizer).  He was also the co-founder and Chief Medical Officer of Cardiokine Inc. and the Chief Executive Officer of Anabase International Corp., which provides regulatory and clinical research services.  Dr. de Lame was a key contributor to many product development teams involving several vaccines and antibiotics.  He was also principally involved with the clinical development of Lipitor® (atorvastatin) and the life cycle management of imipenem/cilastatin (Tienam®, Primaxin®), gemfibrozil, quinapril (Accupril®), norfloxacin and several medical devices.  Dr. de Lame received his M.D. from the Universite Catholique de Louvain, with a specialization in anesthesiology and intensive care.


Fred Kurland, J.D., M.B.A.

Chief Financial Officer

Mr. Kurland has more than 35 years experience in corporate finance, most recently as the CFO of Xoma.  Mr. Kurland has a long and distinguished career as Chief Financial Officer of a number of biotechnology companies including Bayhill Therapeutics, Corcept Therapeutics, Genitope Corporation, Aviron, Protein Design Labs and Applied Immune Sciences, Inc.  Previously, he held a number of financial management positions at Syntex Corporation between 1981 and 1995 including Vice President and Controller between 1991 and 1995.  Mr. Kurland received his B.S. from Lehigh University and his J.D. and M.B.A. degrees from the University of Chicago.


Steven Chamow, Ph.D.

Product Development

Dr. Chamow has more than 25 years of experience in biopharmaceutical product development and contributed to the development of three marketed products (Avastin, Natrecor, Vectibix).  He served in leadership positions at a number of leading biotech companies, including Senior Vice President at Intradigm, Vice President of Process Sciences at Genitope Corporation and at Abgenix, Inc., (acquired by Amgen).  He was also a senior scientist at Genentech.  Dr. Chamow is author or co-author of more than 50 scientific publications and patents and co-editor of two books on therapeutic antibody fusion proteins.  He received his Ph.D. in biochemistry at UC Davis.


Elizabeth Leininger, Ph.D.

Regulatory and QA/QC

Dr. Leininger is an expert in regulatory affairs and quality, with more than 20 years of experience at CBER/FDA and at biopharmaceutical companies.  She previously held senior management positions at Chiron (acquired by Novartis) and GSK.  Additionally, she has significant expertise in global strategic development, licensing and post-marketing regulatory activities for biological and biotechnology products.  She also ran large QA/QC organizations responsible for the evaluation, development and implementation of Quality Systems, including documentation, training and auditing.  Dr. Leininger earned her Ph.D. in chemistry from the University of North Carolina at Chapel Hill.


Jeffrey J. Fessler, J.D.

Acting General Counsel

Mr. Fessler has over 20 years of experience providing corporate and securities legal counsel in the biotechnology industry. He has extensive experience  providing counsel in public offerings and private placements as well as mergers and acquisitions, joint ventures, proxy contests, restructurings and private equity and debt financings.  He is a partner in the Sheppard Mullin law firm, and has practiced corporate and securities law at several large firms, including Akin, Gump, Strauss, Hauer & Feld and Orrick, Herrington & Sutcliffe, and Sichenzia Ross Friedman Ference LLP. Mr. Fessler holds a B.S. degree in Accounting from the University of Maryland and  J.D. (magna cum laude) from New York Law School.

Executive Team

PHARMACEUTICALS

Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis Home